BACKGROUND: Despite extensive studies of atovaquone in human immunodeficiency virus (HIV)-infected patients, there is little information about its efficacy as a prophylactic agent for Pneumocystis carinii pneumonia (PCP) in pediatric patients with cancer. Therefore, a retrospective analysis was conducted to determine the incidence of PCP in pediatric patients who received prophylactic atovaquone during treatment for acute leukemia. METHODS: We reviewed the medical records of all patients treated at our institution for acute lymphoblastic leukemia or acute myeloid leukemia between 1994 and 2004. Only patients who were intolerant of trimethoprim-sulfamethoxazole (TMP-SMZ) and received atovaquone prophylaxis were included in the analysis. RESULTS: Eighty-six patients were unable to tolerate TMP-SMZ and received daily atovaquone for PCP prophylaxis. PCP was not diagnosed in any patient who received atovaquone prophylaxis: the upper limit of the 95% confidence interval (CI) was 1.74 per 100 person-years. CONCLUSIONS: Atovaquone is an efficacious alternative for PCP prophylaxis in pediatric patients who have leukemia and are intolerant of TMP-SMZ.
BACKGROUND: Despite extensive studies of atovaquone in human immunodeficiency virus (HIV)-infectedpatients, there is little information about its efficacy as a prophylactic agent for Pneumocystis carinii pneumonia (PCP) in pediatric patients with cancer. Therefore, a retrospective analysis was conducted to determine the incidence of PCP in pediatric patients who received prophylactic atovaquone during treatment for acute leukemia. METHODS: We reviewed the medical records of all patients treated at our institution for acute lymphoblastic leukemia or acute myeloid leukemia between 1994 and 2004. Only patients who were intolerant of trimethoprim-sulfamethoxazole (TMP-SMZ) and received atovaquone prophylaxis were included in the analysis. RESULTS: Eighty-six patients were unable to tolerate TMP-SMZ and received daily atovaquone for PCP prophylaxis. PCP was not diagnosed in any patient who received atovaquone prophylaxis: the upper limit of the 95% confidence interval (CI) was 1.74 per 100 person-years. CONCLUSIONS:Atovaquone is an efficacious alternative for PCP prophylaxis in pediatric patients who have leukemia and are intolerant of TMP-SMZ.
Authors: Alexandra M Stevens; Michael Xiang; Lisa N Heppler; Isidora Tošić; Kevin Jiang; Jaime O Munoz; Amos S Gaikwad; Terzah M Horton; Xin Long; Padmini Narayanan; Elizabeth L Seashore; Maci C Terrell; Raushan Rashid; Michael J Krueger; Alicia E Mangubat-Medina; Zachary T Ball; Pavel Sumazin; Sarah R Walker; Yoshimasa Hamada; Seiichi Oyadomari; Michele S Redell; David A Frank Journal: Blood Adv Date: 2019-12-23
Authors: Adam J Esbenshade; Richard H Ho; Ayumi Shintani; Zhiguo Zhao; Lesley-Ann Smith; Debra L Friedman Journal: Cancer Date: 2011-01-18 Impact factor: 6.860
Authors: Su Young Kim; Alix A Dabb; Donald J Glenn; Kristen M Snyder; Meredith K Chuk; David M Loeb Journal: Pediatr Blood Cancer Date: 2008-04 Impact factor: 3.167
Authors: K M Williams; K W Ahn; M Chen; M D Aljurf; A L Agwu; A R Chen; T J Walsh; P Szabolcs; M J Boeckh; J J Auletta; C A Lindemans; J Zanis-Neto; M Malvezzi; J Lister; J S de Toledo Codina; K Sackey; J L H Chakrabarty; P Ljungman; J R Wingard; M D Seftel; S Seo; G A Hale; B Wirk; M S Smith; B N Savani; H M Lazarus; D I Marks; C Ustun; H Abdel-Azim; C C Dvorak; J Szer; J Storek; A Yong; M R Riches Journal: Bone Marrow Transplant Date: 2016-01-04 Impact factor: 5.483
Authors: Carolina Bernauer; Y K Stella Man; Julia C Chisholm; Elise Y Lepicard; Simon P Robinson; Janet M Shipley Journal: Br J Cancer Date: 2020-10-27 Impact factor: 7.640